Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above Two Hundred Day Moving Average of $1.41

Spero Therapeutics, Inc. (NASDAQ:SPRO) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.41 and traded as high as $1.54. Spero Therapeutics shares last traded at $1.40, with a volume of 378,240 shares traded.

Analyst Ratings Changes

A number of research firms have recently weighed in on SPRO. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Spero Therapeutics in a research note on Monday, March 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research note on Thursday, April 4th.

Spero Therapeutics Stock Down 4.8 %

The firm has a fifty day moving average price of $1.64 and a two-hundred day moving average price of $1.41. The stock has a market capitalization of $75.45 million, a P/E ratio of 3.33 and a beta of 0.55.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Wednesday, March 13th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of ($0.18) by $1.14. Spero Therapeutics had a return on equity of 38.54% and a net margin of 21.98%. The company had revenue of $73.52 million during the quarter, compared to the consensus estimate of $19.40 million. Sell-side analysts anticipate that Spero Therapeutics, Inc. will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SPRO. Bank of America Corp DE lifted its position in shares of Spero Therapeutics by 132.0% during the 1st quarter. Bank of America Corp DE now owns 18,417 shares of the company’s stock valued at $27,000 after buying an additional 10,479 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Spero Therapeutics during the 1st quarter valued at approximately $95,000. XTX Topco Ltd bought a new stake in Spero Therapeutics during the 1st quarter valued at approximately $115,000. Royal Bank of Canada raised its stake in Spero Therapeutics by 7.4% during the 1st quarter. Royal Bank of Canada now owns 196,097 shares of the company’s stock valued at $1,706,000 after purchasing an additional 13,502 shares during the period. Finally, Jane Street Group LLC bought a new stake in Spero Therapeutics during the 3rd quarter valued at approximately $31,000. 25.60% of the stock is owned by hedge funds and other institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.